MNMasafumi Noda

Masafumi Noda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masafumi Noda has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A case of costal osteochondroma necessitating emergency surgery for hemothorax

    by Tomoko Hosaka, Masafumi Noda, Fumie Nakayama, Noriyuki Iwama, Yoshinori Okada

    肋骨に生じた骨軟骨腫による血胸にて緊急手術を要した1例を経験した.症例は16歳,男性.1ヵ月前より右肩痛を自覚,当初は明らかな異常所見はなく,対症療法を行った.しかし,その後のリハビリテーション中,急に顔色不良,冷汗を認めた.胸部X線検査,CT検査にて,右血胸と診断された.さらに胸部CT上,右第7肋骨後方内側の胸腔内に高吸収構造物を認め,周囲の胸膜脂肪織が肥厚していた.翌日貧血が進行し,胸水も増加したため,胸腔鏡下に手術を施行.右第7肋骨より胸腔内に突出する骨棘を認め,対面する横隔膜面が凹凸・不整があり,その部位から出血したと考えられた.骨棘を摘出したところ,病理診断は骨軟骨腫として矛盾しないものであった.

  • Open Access

    Correction to: Oxidative stress enhances the expression of IL-33 in human airway epithelial cells

    by Hiroyuki Aizawa, Akira Koarai, Yutaka Shishikura, Satoru Yanagisawa, Mutsuo Yamaya, Hisatoshi Sugiura, Tadahisa Numakura, Mitsuhiro Yamada, Tomohiro Ichikawa, Naoya Fujino, et al.

    Figure 2 of this original publication was incorrectly formatted. The updated Fig. 2 is published in this correction article [1].


  • Open Access

    High preoperative plasma vasohibin‐1 concentration predicts better prognosis in patients with non–small cell lung carcinoma

    by Tatsuaki Watanabe, Tomoko Hosaka, Kaori Ohmori‐Matsuda, Yasuhiro Suzuki, Hirotoshi Suzuki, Hiroshi Yabuki, Yasushi Matsuda, Masafumi Noda, Akira Sakurada, Yoshinori Okada, et al.

    Background and Aim: Vasohibin‐1 (VASH1) is an angiogenesis inhibitor synthesized and secreted by endothelial cells, whose expression is induced by angiogenic stimuli such as vascular endothelial growth factor. We have previously demonstrated that VASH1 is immunohistochemically evident in endothelial cells in the tumor microenvironment of patients with non–small cell lung cancer (NSCLC) and is positively correlated with that of vascular endothelial growth factor in cancer cells. Here, we determined the preoperative plasma concentration of VASH1 in patients with NSCLC and evaluated the association between the preoperative VASH1 levels and certain outcomes.Methods: We analyzed presurgical plasma VASH1 concentrations in a total of 79 lung cancer patients (51 males and 28 females; 34‐83 y of age; 46 adenocarcinomas, 27 squamous cell carcinomas, and 6 other types) who underwent lung resection. The impact of preoperative VASH1 level was analyzed using clinical characteristics and prognosis.Results: Plasma VASH1 concentration ranged from 34.1 to 1190.4 fmol/mL. We divided the patients into 3 groups according to plasma VASH1 level for this assessment: low VASH1 group (n = 26), medium VASH1 group (n = 27), and high VASH1 group (n = 26). The death and recurrence rates of the high, medium, and low VASH1 groups were 5.5, 16.2, and 12.7 per 100 person‐years, respectively. Multivariate adjusted hazard ratio of death and recurrence of the high VASH1 group was lower than that of the low VASH1 group (hazard ratio 0.42; 95% CI 0.17‐0.99).Conclusion: The present analysis suggests that high preoperative plasma VASH1 concentration is associated with better prognosis in patients with NSCLC. We propose preoperative VASH1 level as a biomarker for the prognosis of patients with non–small cell lung carcinoma.


  • Bone marrow mesenchymal stromal cells protect allograft lung transplants from acute rejection via the PD-L1/IL-17A axis

    by Naoya Ishibashi, Tatsuaki Watanabe, Masahiko Kanehira, Yui Watanabe, Yasushi Hoshikawa, Hirotsugu Notsuda, Masafumi Noda, Akira Sakurada, Shinya Ohkouchi, Takashi Kondo, et al.

    Using a rat model of allograft lung transplantation, we investigated the effectiveness of mesenchymal stromal cells (MSCs) as prophylactic and therapeutic agents against the acute rejection of lung grafts.


  • A multicenter phase II study of preoperative concurrent chemoradiotherapy with S-1 plus irinotecan for locally advanced rectal cancer: SAMRAI-2

    by M. Noda, T. Sato, K. Hayakawa, N. Tomita, N. Kamikonnya, S. Matoba, A. Uki, H. Baba, N. Oya, H. Hasegawa, et al.

    Background: We previously conducted a phase I study of preoperative concurrent chemoradiotherapy combining S-1 and irinotecan with radiotherapy of the lesser pelvis in patients with resectable, locally advanced rectal cancer (SAMRAI-1 Trial). The maximum tolerated dose (MTD) of irinotecan was 80 mg/m2, and the recommended dose was 60 mg/m2. We thus conducted a phase II study (SAMRAI-2 Trial) to further evaluate efficacy and safety.


  • Incidence and Therapeutic Outcome of Pouchitis for Ulcerative Colitis in Japanese Patients

    by Hiroki Ikeuchi, Hiroki Nakano, Motoi Uchino, Mitsuhiro Nakamura, Hidenori Yanagi, Masafumi Noda, Takehira Yamamura

    Aim: The aim of this study was to examine the cumulative risk of pouchitis following restorative proctocolectomy for UC and FAP in Japanese patients, and to assess the response to medical treatment and its outcome. Patients and Methods: 521 patients with UC and 117 FAP patients underwent proctocolectomy and received a J-shaped IPAA at our department of surgery. We investigated these patients using PDAI for the diagnostic criteria of pouchitis. Results: Pouchitis occurred in only 32 UC patients (6.1%). The cumulative risk of developing pouchitis for a UC patient was 7% at 5 years after and 12% at 10 years after surgery. The medical treatment of acute pouchitis was usually oral metronidazole (250 mg twice daily) for 2 weeks or oral ciprofloxacin (200 mg thrice daily) in patients who could not tolerate metronidazole. Single episodes of pouchitis occurred in 21 patients (65.6%) and chronic or frequent relapses of pouchitis in 11 patients (34.4%). Three patients (9.4%) required re-ileostomy. Two patients (6.3%) required pouch excision. There were no patients with complicated dysplasia. Conclusion: The cumulative risk of pouchitis in Japanese UC patients is lower than that of western countries.